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INTRODUCTION
The characteristic diversity of colorectal cancer (CRC) is thought 
to be due to its unique genetic and/or epigenetic oncogene-
sis.1 Although cancer stem cells (CSCs) constitute only a mi-
nor tumor population, they have a major role in tumor main-
tenance and recurrence,2,3 as well as in initiation of organized 
carcinogenesis. In the last two decades, several markers, in-
cluding CD133, CD44, CD166, CD24, ALDH1, LGR5, and 
EPhB2, have been identified as CSC markers in CRC.1 Based 
on these markers, numerous studies have been performed to 
evaluate the clinical relevance of these putative CSCs in CRC 
survival,4,5 progression,3,6,7 and therapeutic feasibility.8,9
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Purpose: Wnt and mammalian target of rapamycin (mTOR) are major molecular signaling pathways associated with the devel-
opment and progression of tumor, as well as the maintenance and proliferation of cancer stem cells (CSCs), in colorectal cancer 
(CRC). Identifying patients at risk of poor prognosis is important to determining whether to add adjuvant treatment in stage II CRC 
and thus improve survival. In the present study, we evaluated the prognostic value of Wnt, mTOR, and CSC markers as survival 
predictors in stage II CRC.
Materials and Methods: We identified 148 cases of stage II CRC and acquired their tumor tissue. Tissue microarrays for immuno-
histochemical staining were constructed, and the expressions of CD166, CD44, EphB2, β-catenin, pS6 were evaluated using im-
munohistochemical staining.
Results: The expressions of CD166 (p=0.045) and pS6 (p=0.045) and co-expression of pS6/CD166 (p=0.005), pS6/CD44 (p=0.042), 
and pS6/CD44/CD166 (p=0.013) were negatively correlated with cancer-specific survival. Cox proportional hazard analysis 
showed the combination of CD166/pS6 [hazard ratio, 9.42; 95% confidence interval, 2.36–37.59; p=0.002] to be the most signifi-
cant predictor related with decreased cancer-specific survival. In addition, co-expression of CD44/CD166 (p=0.017), CD166/
β-catenin (p=0.036), CD44/β-catenin (p=0.001), and CD44/CD166/β-catenin (p=0.001) were significant factors associated with 
liver metastasis. 
Conclusion: Specific combinations of CSC markers and β-catenin/mTOR signaling could be a significant predictor of poor sur-
vival in stage II CRC.
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Signaling pathways that can induce Wnt/β-catenin and mam-
malian target of rapamycin (mTOR) play fundamental roles in 
early carcinogenesis, CSC maintenance, and CRC progression. 
Under normal circumstances, Wnt signaling regulates the pro-
liferation and differentiation of stem cells, as well as embryonic 
development and tissue homeostasis, by controlling amounts 
of β-catenin.10 In cancer development, Wnt/β-catenin signaling 
is activated by either a mutation that results in loss of function 
of the adenomatosis polyposis coli gene or a β-catenin muta-
tion, which subsequently leads to accumulation of β-catenin 
and cancer development.11-13 In addition, phosphatidylinosi-
tol-3-kinase (PI3K)/Akt/mTOR signaling is another key mo-
lecular signal for sustaining tumor growth and metastasis.14 
mTOR is activated by its upstream effector, Akt, and regulates 
cell growth and proliferation by mediating multiple signals, 
including growth factors, nutrients, hormones, and energy or 
stress status.14-16 The ribosomal protein pS6 is a marker of active 
mTOR signaling and plays a role in cell survival, proliferation, an-
giogenesis, and protein synthesis.17 Thus, Wnt and mTOR in-
hibitors have been researched as potential targets for anti-can-
cer therapy.16 
With respect to clinical aspects of CRC treatment, identifi-
cation of poor prognostic molecular markers in stage II CRC is 
an important issue for improving survival, helping clinicians 
discern whether to add more aggressive adjuvant chemother-
apy. However, the clinical relevance of several putative mark-
ers of CSCs or molecular signals has been evaluated in only a 
few studies, and there has been no comprehensive analysis of 
the combined expression of these markers as prognostic fac-
tors in stage II CRC. Thus, in the present study, the expression 
patterns of CSC markers (CD166, CD44, EPhB2) and major 
target signal markers (β-catenin, pS6) using tissue microarray 
(TMA) were evaluated, and the association of their combined 
expression with long-term survival outcomes in stage II CRC 
patients was assessed. 
MATERIALS AND METHODS
Study subjects and data collection 
We identified all cases of resected CRCs at Severance Hospi-
tal, Yonsei University College of Medicine, Seoul, Korea be-
tween December 2002 and July 2006. Patients diagnosed with 
stage II colorectal adenocarcinoma without previous treat-
ment were included. Patients who fulfilled any of the follow-
ing criteria were excluded: 1) history of other malignant disease; 
2) other types of CRC, including squamous cell, neuroendo-
crine, or spindle cell carcinoma; 3) familiar polyposis syn-
drome, including familial adenomatous polyposis, or Lynch 
syndrome; or 4) inadequate medical information or any error 
in immunohistochemical staining (IHCS) of the five markers. 
The Institutional Review Board of Severance Hospital approved 
this study (IRB number; 4-2018-1174). 
TMA construction and IHCS
TMAs were constructed after review of hematoxylin and eosin 
stained slides by a pathologist for selection of representative 
tumor areas. Two cores from the primary cancer and one core 
from normal tissue 2 mm in diameter were punched from the 
paraffin blocks for tissue array blocks. Each tissue array block 
contained 48 cores consisting of 16 cases.
TMA paraffin blocks were serially cut to a thickness of 4 μm. 
After deparaffinization and rehydration, antigen retrieval was 
performed using citrate buffer (10 mM, pH 6.0). IHCS using an-
ti-CD166, anti-CD44, β-catenin (Santa Cruz, Delaware, CA, 
USA), anti-EphB2, and anti-pS6 antibodies (Cell Signaling Tech-
nology, Danvers, MA, USA) was performed on the TMA slides. 
After 30 min of incubation with a Vectastain ABC kit (Vector 
Labs, Burlingame, CA, USA), sections were visualized using di-
aminobenzidine solution. TMA sections were counterstained 
with hematoxylin for 1 min, dehydrated in 70%, 80%, 90%, and 
100% ethanol, cleared in xylene, and mounted in Balsam. A 
negative control of IHCS was made by applying a secondary 
antibody without a primary antibody.
Scoring of CD166, CD44, EphB2, β-catenin, and pS6 
expression 
CD166, CD44, and EphB2 were evaluated as CSC markers,1 
nuclear β-catenin as a canonical Wnt/β-catenin signal10 and 
pS6 as a marker of active mTOR signaling.18 IHCS of each mark-
er was evaluated by two trained researchers (Ji Young Chang 
and Jae Hyun Kim). The IHCS of CD44, EphB2, and nuclear 
β-catenin was evaluated based on the staining intensity of pos-
itive tumor cells (Supplementary Fig. 1, only online). Staining 
intensity was scored using the following 4-point scale: 0 for 
negative staining; 1 for weak, light yellow staining; 2 for moder-
ate, yellowish brown staining; and 3 for strong, brown staining 
(Supplementary Fig. 1, only online).19 The expressions of CD166 
and pS6 were evaluated as positive or negative, because IHCS 
for CD166 and pS6 is relatively weaker than that for other mark-
ers (Supplementary Fig. 1, only online).5
Data collection and assessment
Clinical and pathologic data were collected by reviewing med-
ical records. Tumor staging was evaluated based on the sev-
enth edition of the American Joint Committee on Cancer/
Union International Control Center (AJCC/UICC) TNM stag-
ing manual. Histological classification of CRC was evaluated 
based on the World Health Organization classification.20 Clin-
ical high-risk features for poor prognosis included poorly dif-
ferentiated histology, presence of lymphovascular invasion, 
presence of perineural invasion, less than 12 lymph nodes re-
ported, bowel obstruction, localized perforation, or positive 
margins.21 Overall survival was defined as survival from the 
time of treatment to death due to any cause, whereas cancer-
specific survival was defined as survival from the time of treat-
ment to colon cancer-related death.22 
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Statistical analyses 
All statistical analyses were conducted using SPSS version 
22.0 (IBM Corp., Armonk, NY, USA). Student’s t-tests were used 
for continuous variables, and the chi-square test, Fisher’s exact 
test, or linear-by-linear association was used for categorical vari-
ables. The Kaplan-Meier method and the log-rank test were 
performed to identify cumulative survival rates based on marker 
expression. Furthermore, Cox proportional hazard analysis was 
performed to identify independent predictive factors for long-




A total of 190 patients were found to have stage II CRC and 
underwent surgery. Of these, 148 patients who showed ade-
quate IHCS quality and good medical compliance were includ-
ed in this study. A detailed flowchart of study subjects is shown 
in Fig. 1. Baseline characteristics of the study subjects are 
shown in Table 1. The median age of the study population was 
62.0 years [interquartile range (IQR), 54.0–68.0], and 62.8% were 
male. Based on the AJCC/UICC staging system, 146 (98.6%) cas-
es were T3, and the other 2 cases (1.4%) were T4. The median 
tumor size was 5.0 cm (IQR, 4.0–6.4). High-risk features were 
found in 72 patients [poorly differentiated histology, 5 (3.4%); 
presence of lymphovascular invasion, 40 (27.0%); presence of 
perineural invasion, 14 (9.5%); less than 12 lymph nodes re-
ported, 10 (6.8%); bowel obstruction, 1 (0.7%); positive mar-
gins, 2 (1.4%); respectively]. In treatment with adjuvant che-
motherapy, we found that a relatively high portion of patients 
had received chemotherapy, even in patients with stage II CRC 
without high risk features. A 5-fluorouracil (5-FU)/leucovorin 
(LV) regimen was most frequently prescribed (125, 93.3%), fol-
lowed by capecitabine (6, 4.5%) and FOLFOX (5-FU/LV/oxali-
platin) regimens (3, 2.2%). The median follow-up duration was 
Table 1. Baseline Characteristics of the Study Subjects
Characteristics n=148
Age at diagnosis (yr) 62.0 (54.0–68.0)
Male sex 93 (62.8)



















High-risk features 72 (48.6)
Chemotherapy 134 (90.5)
Follow-up duration (yr) 12.2 (11.0–13.4)
IQR, interquartile range; CEA, carcinoembryonic antigen.
Data are presented as number (%) or median (IQR).
*Undifferentiated histology included poorly differentiated, mucinous adeno-
carcinoma, and signet-ring cancer subtype. 
Patients confirmed with CRC and underwent surgery from 
December 2002 to July 2006 (n=190)
Patients with IHCS for cancer stem cell markers 
(n=175)
Exclusion (n=27) 
- Any error in IHCS among 5 markers
Exclusion (n=15) 
- Other malignant disease (n=4)
- Metachronous CRC (n=7)
- Familial adenomatous polyposis (n=1)
- Follow-up loss after surgery (n=3)
Finally included patients (n=148)
Fig. 1. Flow chart of the enrolled study subjects. CRC, colorectal cancer; IHCS, immunohistochemical staining.
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12.2 years (IQR, 11.0–13.4). 
IHCS staining and survival analysis 
The proportions of positive expression of CD166, CD44, EphB2, 
β-catenin, and pS6 were 61.5% (91 cases), 51.4% (76 cases), 
14.9% (22 cases), 60.8% (90 cases), and 23.6% (35 cases), respec-
tively. Within the median follow-up period, 30 patients died, 
and 11 deaths were associated with CRC progression. 
Using Kaplan-Meier survival curves, the association be-
tween overall survival rate and the expression of each individ-
ual marker or combinations thereof were analyzed. pS6 ex-
pression (p=0.004) and co-expression of pS6/CD166 (p=0.003), 
pS6/CD44 (p=0.002), pS6/CD166/CD44 (p=0.008), and pS6/
CD166/β-catenin (p=0.040) were significantly correlated with 
low survival (Supplementary Fig. 2, only online). Cox multi-
variate adjusted analysis for overall survival showed clinical 
factors of age and chemotherapy and IHCS markers pS6 (p= 
0.002), pS6/CD44 (p<0.001), pS6/CD166 (p<0.001), pS6/
CD166/CD44 (p=0.001), and pS6/CD166/ β-catenin (p=0.008) 
were significant. Detailed results from the univariate and mul-
tivariate analyses for overall survival are provided in Supple-
mentary Tables 1 and 2 (only online). 
As for cancer-specific survival, Kaplan-Meier analysis showed 
CD166 (p=0.045), pS6 (p=0.045), and co-expression of pS6/
CD166 (p=0.005), pS6/CD44 (p=0.042), and pS6/CD166/CD44 
(p=0.013) were significant factors (Fig. 2). In univariate analy-
sis, preoperative CEA>5 ng/mL (p=0.006) and presence of 
high-risk features (p=0.041) were associated with decreased 
cancer-specific survival, whereas chemotherapy (p=0.046) was 
correlated with improved cancer-specific survival. In addition, 
the co-expression of pS6/CD166 (p=0.010), and pS6/CD166/
CD44 (p=0.022) was significantly associated with poor cancer-
specific survival (Table 2). After adjusting for clinically rele-
vant factors, the IHCS markers pS6 (p=0.018), pS6/CD166 (p= 
0.002), pS6/CD44 (p=0.015), CD166/CD44 (p=0.034), pS6/
CD166/β-catenin (p=0.035), and pS6/CD166/CD44 (p=0.005) 
were negatively correlated with cancer-specific survival in mul-
tivariate Cox analysis (Table 3). The expression of pS6/CD166 
[hazard ratio (HR), 9.42; 95% confidence interval (CI), 2.36–
37.59; p=0.002] was identified as the most influential factor 
along with chemotherapy (HR, 0.14; 95% CI, 0.03–0.71; p=0.017) 
among clinically relevant factors. Detailed multivariate results 
for IHCS markers and their combinations are shown in Sup-
plementary Table 3 (only online).
With respect to recurrence, there were 20 recurrences (13.5%) 
among 148 patients, and the estimated 3- and 5-year recur-
rence free survival rates were 92.8% and 86.5%, respectively. 
However, there was no significant association between specif-
Fig. 2. Kaplan-Meier curves showing cumulative cancer-specific survival rates in stage II colorectal cancer based on the expression of CD166, CD44, 
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ic expression of CSC markers and/or β-catenin/mTOR signals 
and recurrence of CRC.
In subgroup analysis, the influence of specific expression of 
CSC markers and/or β-catenin/mTOR signals on recurrence 
with liver metastasis was analyzed. Univariate analysis showed 
co-expression of CD44/CD166 (p=0.017), CD166/β-catenin (p= 
0.036), CD44/β-catenin (p=0.001), and CD44/CD166/β-catenin 
(p=0.001) to be significant factors associated with liver metas-
tasis (Supplementary Fig. 3, only online). Multivariate analysis 
was not performed due to the small number of events.
DISCUSSION
In this study, combined expression of specific CSC markers 
(CD166, CD44) and an mTOR signaling marker (pS6) were in-
dependently associated with cancer-specific survival, as well 
as overall survival, in stage II CRC. Among the combinations of 
these markers, co-expression of CD166 and pS6 was most neg-
atively correlated with cancer-specific survival. However, pre-
viously known high-risk features did not significantly affect 
cancer-specific survival, whereas chemotherapy improved 
cancer-specific survival. Specific combinations of the expres-
sion of CSC markers (CD166, CD44) and Wnt signal marker 
(β-catenin) were found to have a significant role in liver metas-
tasis. 
Stage II CRC has heterogeneous characteristics regarding 
curability after surgery.21 Although stage II CRC has not spread 
to a lymph node, the risk of micrometastatic disease that could 
develop into macrometastatic disease is present. Thus, the 
American Society of Clinical Oncology23 and the European So-
ciety of Medical Oncology24 have recommended adjuvant che-
motherapy in selected patients with clinical high-risk features. 
However, opinions differ regarding the effectiveness of adjuvant 
chemotherapy based on known high-risk features. O’Connor, et 
al.25 reported that adjuvant chemotherapy did not improve 
overall survival in patients with (HR, 1.03; 95% CI, 0.94–1.13) or 
without poor prognostic features (HR, 1.02; 95% CI, 0.84–1.25) 
in stage II CRC. Thus, to identify other molecular predictors of 
the clinical impact of adjuvant chemotherapy, the assessment 
of mismatch repair deficient or microsatellite instability (MSI) 
has emerged. MSI is caused by abnormality in the DNA mis-
match repair pathway. In stage II CRC, patients with MSI-high 
have been shown to be associated with better overall survival 
(HR, 0.31; 95% CI, 0.14–0.72)26 and worse overall survival 
when they received fluorouracil-based adjuvant chemotherapy 
(HR, 2.95; 95% CI, 1.02–8.54).27 However, these approaches 
have limitations because most of the studies regarding MSI were 
retrospective and only the role of fluorouracil-based regimens 
was evaluated. 
In recent years, attention has increased on carcinogenesis 
signaling pathways and CSC markers as predictors of cancer 
prognosis, as well as targets for cancer prevention and treatment. 
In multi-step carcinogenesis, the signaling pathway represents 
the overall process of carcinogenesis and tumor progression, 
and provides the basis for the genetic diversity of individual 
cancers.1 In addition, CSCs, which constitute only a small frac-
tion of the tumor, exhibit properties of clonogenicity, differen-
tiation, tumor initiation, recurrence, and metastasis.28 In partic-
ular, CSCs are resistant to conventional chemotherapy because 
they have a slow cell cycle and intrinsic defense mechanisms.4 
CD133, CD44, CD166, CD24, ALDH-1, LGR5, EpCAM, and 
EphB2 are considered typical CSC markers of CRC,1,29 and 
most are related to the Wnt/β-catenin signaling pathway. There-
fore, in addition to prognostic markers of CSC related to Wnt/
Table 2. Univariate Analysis for Clinicopathologic Factors and Markers 
of Immunohistochemical Stains Related to Cancer-Specific Survival in 
Stage II Colorectal Cancer
HR 95% CI p value
Sex (female vs. male) 1.42 0.13–4.66 0.562
Age (>60 vs. ≤60 yr) 3.38 0.73–15.65 0.120
CEA (>5 vs. ≤5 ng/mL) 6.37 1.69–24.02 0.006
Size (>5 vs. ≤5 cm) 1.82 0.48–6.88 0.375
Histologic differentiation (well/moderate 
  vs. undifferentiated/poorly)
0.05 0.0–84100.0 0.677
Chemotherapy (yes vs. no) 0.26 0.07–0.98 0.046
High-risk feature* (yes vs. no) 4.95 1.07–22.94 0.041
Marker expression
CD166 (+) vs. CD166 (-) 6.28 0.80–48.13 0.080
CD44 (+) vs. CD44 (-) 1.59 0.46–5.48 0.460
EphB2 (+) vs. EphB2 (-) 0.04 0.0–52.43 0.377
β-catenin (+) vs. β-catenin (-) 0.74 0.23–2.42 0.618
pS6 (+) vs. pS6 (-) 2.93 0.89–9.61 0.076
CD166/CD44 (+/+) vs. others 3.14 0.92–10.77 0.069
pS6/CD166 (+/+) vs. others 4.76 1.45–15.61 0.010
pS6/CD44 (+/+) vs. others 3.32 0.97–11.38 0.056
pS6/CD166/CD44 (+/+/+) vs. others 4.22 1.23–14.44 0.022
HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen.
*High-risk features include poorly differentiated histology, presence of lym-
phovascular invasion, presence of perineural invasion, bowel obstruction, lo-
calized perforation, or positive margins. 
Table 3. Cox Multivariate Adjusted Analysis* for Markers of Immunohisto-
chemical Stains Related to Cancer-Specific Survival in Stage II Colorectal 
Cancer
HR 95% CI p value
pS6 (+) vs. pS6 (-) 4.94 1.32–18.50 0.018
pS6/CD166 (+/+) vs. others 9.42 2.36–37.59 0.002
pS6/CD44 (+/+) vs. others 5.36 1.38–20.81 0.015
CD166/CD44 (+/+) vs. others 4.39 1.12–17.19 0.034
pS6/CD166/β-catenin (+/+/+) vs. others 7.05 1.15–43.18 0.035
pS6/CD166/CD44 (+/+/+) vs. others 7.11 1.82–27.69 0.005
HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen.
*Adjusted for sex, age, CEA, tumor size, chemotherapy, high-risk features. 
577
Ji Young Chang, et al.
https://doi.org/10.3349/ymj.2020.61.7.572
β-catenin, we attempted to find more precise prognostic mark-
ers by adding mTOR signaling, which could be a prognostic mo-
lecular signal similar to Wnt/β-catenin. 
Based on adjusted multivariate analysis, combinations of 
CSC markers and two major CRC signaling pathways were as-
sociated with poor survival; the expression of each CSC marker 
alone was not associated with cancer-specific survival. The ex-
pression of CD44 or CD166 when combined with the expres-
sion of pS6 showed significant associations with poor can-
cer-specific survival. Our results showed that combinations of 
specific markers for CSC and mTOR had better predictive pow-
er for long-term prognosis than previously known high-risk 
features of poor prognosis in stage II CRC. In particular, the 
combination of CD166 and pS6 had the best predictive power 
for cancer-specific survival. 
The mTOR signaling pathway is also a key dysregulated 
pathway in carcinogenesis that facilitates tumor invasion by 
modulating tumor metabolism, autophagy, cellular transfor-
mation, tumor progression, cell survival, and chemotherapy re-
sistance.30,31 mTOR signals can be activated through the ERK/
MAPK and PI3K/AKT pathways induced by receptor tyrosine 
kinases, including EGFR and insulin receptor.31 In addition, a 
relationship between the EGFR/RAS/ERK/MAPK or PI3K/AKT 
pathways and CSCs has been reported in CRC.32-34 Therefore, 
the combination of CSC markers and active mTOR signals could 
suggest more aggressive tumor characteristics with metastasis 
and resistance to chemotherapy via synergic interactions. 
Regarding liver metastasis, CD44 expression has been re-
ported to be associated with increased risk of liver metastasis,4,32 
although whether CD44 alone is sufficient is unclear. Bellizzi, et 
al.35 found the primary colon cancer compartment had a higher 
burden of CD133-positive cells and a lower burden of CD44-
positive cells than the metastatic compartment. In addition, all 
samples from metastatic patients showed a CD133+/CD44+ phe-
notype, and samples from non-metastatic patients had a higher 
prevalence of the CD133+/CD44- phenotype. Based on these 
findings, the authors emphasized the importance of co-expres-
sion of both markers in liver metastasis, suggesting the roles 
of CD133 in tumor growth and CD44 in tumor metastasis. In 
another study, β-catenin, a key component of Wnt signaling, 
was reported to be a liver metastasis predictor based on results 
showing significant accumulation of β-catenin at the invasive 
front and in vessels of samples from patients with liver metas-
tasis, compared to patients without liver metastasis.36 In addi-
tion, the expression of CD44 and CD166 as CSC markers showed 
an overlap in tumor populations, and co-expression of both 
markers highlighted a select CSC population with more prom-
inent characteristics of CSCs.37-39 Moreover, Wnt signaling is a 
major pathway involved in proliferation and maintenance of 
stem cells in normal and cancers, and CD44 is one of the targets 
of Wnt signaling.1 Therefore, the finding of combined CD44/
CD166/β-catenin expression in the present study could be the 
most significant predictive marker associated with liver metas-
tasis in stage II CRC. 
In conclusion, specific combinations of CSC markers and 
an mTOR signal marker were independently associated with 
poor prognosis in stage II CRC. These combinations were also 
found to have better predictive power than previously described 
high-risk features or CSC markers alone. Thus, evaluation of 
these markers could be useful for selecting patients who will re-
quire more aggressive adjuvant chemotherapy or target-spe-
cific adjunctive treatments. Further clinical data from large-
scale studies and prospective trials are needed to confirm these 
findings. 
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